secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immuneering Corp (IMRX)
CIK:        0001790340
Form:       8-K
Filed at:   2022-01-18T23:59:59+00:00
Accession:  0001104659-22-004651
Event type: leadership
Sentiment:  positive
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immuneering appoints Diana F. Hausman, M.D. to Board of Directors
-----------------------------------------------------------------

- Dr. Hausman appointed Class I Director effective January 14, 2022; Board now has six members.
- She brings over 20 years of clinical drug development experience, including CMO roles at Zymeworks and Oncothyreon.
- Currently Chief Medical Officer of Lengo Therapeutics, a wholly-owned subsidiary of Blueprint Medicines (Nasdaq: BPMC).
- No committee assignment yet; will receive standard non-management director compensation.
- Her expertise in oncology and RAS mutant solid tumors supports lead candidate IMM-1-104 development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1790340/000110465922004651/0001104659-22-004651-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1790340/000110465922004651/tm223100d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-004651

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer